Archives
-
CHAP Model for Bleeding Risk in Extended VTE Therapy
2026-08-27
This prospective multinational cohort study evaluated bleeding prediction during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism and introduced the CHAP model based on creatinine, hemoglobin, age, and antiplatelet use. CHAP showed discrimination comparable to modified established scores while using continuous predictors, but external validation remains necessary before routine clinical implementation.
-
Z-VAD-FMK and RIP1: A Translational Cell-Death Strategy
2026-08-27
Translational cell-death research increasingly depends on separating upstream inflammatory signaling from downstream execution. This article positions Z-VAD-FMK as a mechanistic probe for caspase dependence and places it alongside RIP1 inhibition to help researchers design more interpretable apoptosis, immune-regulation, and tissue-injury studies.
-
Z-YVAD-FMK: Translating Pyroptosis Mechanisms
2026-08-26
A mechanistic and translational guide to using Z-YVAD-FMK as a caspase-1 inhibitor in pyroptosis research, inflammasome activation studies, apoptosis assays, and cancer research.
-
Cyclic di-GMP: Biofilm and STING Workflows
2026-08-26
Cyclic di-GMP connects two practical research areas: biofilm persistence and STING-driven immune modulation. This workflow guide translates its antitoxin activity into bacterial assays while outlining controlled, exploratory use in cancer immunotherapy studies.
-
Low-Molecular-Weight Inhibitors of Complement
2026-08-25
The reference review explains how dysregulated alternative complement activity drives diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and age-related macular degeneration. Its central contribution is a mechanistic and translational framework for developing selective, orally available low-molecular-weight inhibitors of factor B and factor D, while clarifying the assays and disease models needed to evaluate them.
-
MDM1, p53, and Chemoradiotherapy Sensitivity in CRC
2026-08-25
A 2025 Cancer Biology & Medicine study identifies MDM1 as a regulator of TP53 expression and chemoradiotherapy response in colorectal cancer. Its genetic, transcriptomic, cellular, and xenograft evidence supports MDM1 as a candidate predictive biomarker and points to apoptosis-focused combination strategies for tumors with low MDM1 expression.
-
Z-WEHD-FMK in Caspase-1 Pyroptosis Studies
2026-08-24
Z-WEHD-FMK is a cell-permeable, irreversible inhibitor for testing inflammatory caspase activity across pyroptosis, infection, and tumor-cell models. This workflow separates validated Chlamydia applications from exploratory NSCLC experiments inspired by the HOXC8–caspase-1 study, helping researchers choose controls and interpret incomplete pathway blockade.
-
Bacitracin B1670: Practical Protocol and QC Guide
2026-08-24
Bacitracin B1670 is a peptide antibiotic reagent for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, assay setup, controls, and product-specific QC boundaries; it is not intended for diagnostic, clinical, therapeutic, or medical use.
-
Z-YVAD-FMK: Reading Caspase-1 Biology
2026-08-23
Z-YVAD-FMK is a cell-permeable, irreversible caspase-1 inhibitor for dissecting inflammasome signaling, pyroptosis, and related cell-death phenotypes. This article connects its use to gasdermin-resolved assay design and explains why inhibition should be paired with pathway-specific readouts.
-
Z-VAD-FMK: Practical Apoptosis Workflow
2026-08-22
Learn how Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone), SKU A1902, can clarify caspase-dependent viability and apoptosis results in THP-1, Jurkat, and other cell models. This scenario-based guide covers experimental controls, DMSO handling, protocol optimization, interpretation, and practical product selection.
-
Exo1 for Exocytosis and Membrane Trafficking
2026-08-22
Exo1 enables acute, mechanistically distinct inhibition of ER-to-Golgi traffic for exocytosis assays, secretory-pathway mapping, and ARF1-focused experiments. This guide connects that bench workflow to tumor extracellular-vesicle research while clearly separating validated product behavior from exploratory applications.
-
Saracatinib (AZD0530) Experimental Workflow
2026-08-21
Build a controlled Saracatinib workflow for Src/Abl pathway interrogation, cancer cell proliferation inhibition, and migration studies. The guide also explains how findings on Reelin–SFK signaling can inform assay design without overstating cross-domain evidence.
-
Lipidated Nanophotosensitizer Blocks Tumor Spread
2026-08-20
The reference study introduces a palmitic-acid-displayed nanoparticle that both traces tumor extracellular vesicles and delivers photodynamic damage to intracellular and vesicular compartments. Its dual-distribution strategy suppresses primary tumors while disrupting TEV-mediated communication and metastasis in multiple mouse models, suggesting a way to address tumor growth and dissemination within one spatially coordinated treatment.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-20
The reference study identifies striatal D2 receptor-expressing medium spiny neurons as a cell-type-specific circuit node linking Neuroligin 1 loss to excessive self-grooming and digging. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, it implicates abnormal PKC signaling and distinct activity patterns in restricted and repetitive behavior.
-
Neurospora crassa Auxin Biosynthesis via the IPA Pathway
2026-08-19
Sardar and Kempken characterized an indole-3-pyruvic acid pathway for indole-3-acetic acid biosynthesis in Neurospora crassa by combining computational gene identification, metabolite analysis, and targeted mutants. Their results connect candidate fungal genes to IAA production and conidiation, providing a useful framework for fungal auxin biology and comparative plant hormone research.